← Back to Clinical Trials
Recruiting Phase 3 NCT01917552

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Gastric Cancer
Sponsor Asan Medical Center
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 870
Sex ALL
Min Age 18 Years
Max Age 74 Years
Start Date 2013-08-19
Completion 2026-08-01
Interventions
capecitabine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

multi-center, prospective, randomized, open-label phase III

Eligibility Criteria

Inclusion Criteria: * Curatively resected gastric or gastroesophageal junction adenocarcinoma * Pathologic stage IB (by AJCC 6th edition) with at least one additional risk factor for recurrence (additional risk factors for recurrence include age \>65 years, male gender, presence of lymphovascular invasion, presence of perineural invasion). * Age: 18 -74years * ECOG performance status: 0-2 * Adequate bone marrow function (ANC \>1,500/uL, Platelets 100,000/uL, and Hb \> 8.0 g/dL) * Adequate renal function (serum creatinine \< 1.5 mg/dL) * Adequate hepatic function (bilirubin \< 1.5 mg/dL, ALT and AST \< 3 times upper limit of normal) * Written informed consent Exclusion Criteria: * Pregnant or lactating women. * Women of childbearing potential with either a positive pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child bearing potential. * Sexually active males and females (of childbearing potential) unwilling to

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}